Comet assay for detection of DNA damage caused by hepatitis C virus induced cirrhosis and hepatocellular carcinoma

Thesis submitted for partial fulfillment of Master degree in clinical and chemical pathology

by

Aliaa Sayed El Dash M.B.B.CH

Supervised by

Prof. Dr. Shereen Mahmoud Shawky

Professor of Clinical and Chemical Pathology Cairo University

Dr. Mariam Onsy Farag Hanna

Assistant Professor of Clinical and Chemical Pathology
Cairo University

Dr. Safa Sayed Meshaal

Lecturer of Clinical and Chemical Pathology
Cairo University

Faculty of Medicine Cairo University 2012

ACKNOWLEDGEMENT

I am deeply thankful to almighty ALLAH by the grace of whom the progress and success of this work was possible.

I am profoundly grateful to **Prof. Dr. Shereen Mahmoud Shawky**, Professor of Clinical and Chemical Pathology, Faculty of medicine, Cairo University, for her great scientific supervision, indispensable comments and real support.

I am very grateful and thankful to **Dr. Mariam Onsy Farag Hanna**, Assistant Professor of Clinical and Chemical Pathology, Faculty of medicine, Cairo University, for her valuable suggestions, encouragement, solving the scientific problems I faced and for her continual follow up from the beginning to the end of this research project.

I am sincerely indepted and profoundly grateful to **Dr. Safa Sayed Meshaal** Lecturer of Clinical and Chemical Pathology, Faculty of medicine, Cairo University, for her kind supervision, expert guidance and advice and her great effort in revising this study. So I would really like to express my cordial thanks and profound gratitude to her.

I wish to express my sincere appreciation to **Dr. Naglaa Ali Zayed**, Assistant Professor of Tropical medicine, Faculty of medicine, Cairo University, for her valuable direction concerning the clinical part of the study.

I would like to express my thanks to the whole staff members of the Clinical and Chemical pathology department, Faculty of medicine, Cairo university. And to everyone who made this work possible, I am indeed very thankful.

LIST OF CONTENTS

List of abbreviations	Α
List of tables	D
List of figures	F
Abstract	
Introduction and aim of work	, III
Review of literature	
Chapter 1: Hepatitis c virus infection	.1
 Structure of HCV virions	
Chapter 2: Hepatocellular carcinoma2	24
 Incidence	
• Diagnosis	
Mechanisms of carcinogenesis in hepatitis C virus associated liver cancer	

Chapter3: DNA damage	40
 Consequences of DNA damage	41 43 48 48
 Introduction Common Comet Assay Variants Evaluation and interpretation of results Applications of the Comet assay Limitations of the Comet assay 	55 56 59
Patients and methods	63
Results	74
Discussion	97
Summary and conclusion	104
References	106
Appendix	
individual data of patients and controls	134
Arabic summary	

LIST OF ABBREVIATIONS

- 2'-5' OAS: Oligoadenylate synthetase
- **6–4 PPs:** 6–4 pyrimidine-pyrimidone photoproducts
- **8-OHdG**: 8-hydroxydeoxyguanosine
- 8-oxoG: 8-oxo-7,8-dihydroguanine
- ADAR: Adenosine deaminase-RNA-specific
- ALT: Alanine aminotransferase
- Anti-LKM : Anti-liver-kidney microsomes
- AP: Apurinic/ apyrimidinic sites
- **APC:** Antigen-presenting cells (APC)
- **AST**: Aspartate aminotransferase
- ATM: Ataxia telangiectasia mutated kinase
- BER: Base excision repair
- CARDIF: CARD adaptor inducing IFN-β CARDIF
- cDC: conventional DC
- Chk2: Checkpoint kinase 2
- CPD: Cyclobutane Pyrimidine Dimer
- CTL: cytotoxic T lymphocyte
- **DAPI:** 4,6-diamidino-2-phenylindole
- **DC**: Dendritic cells
- **DI H2O:** Di-ionized water
- DNA: DeoxyriboNucleic Acid
- **DSB:** Double-Strand Break
- ds-RNA: double-stranded RNA
- **EB**: Ethidium bromide
- EDHS: Egypt Demographic and Health Survey
- **EIA:** Enzyme immunoassay
- **ELISA**: Enzyme-linked immunosorbent assay
- **FCM:** Flow cytometry
- **FISH:** Fluorescence in situ hybridization

• FoxP3: Forkhead box P3

• FPG: formamidopyrimidine DNA glycosylase

• **GC-MS**: Gas chromatography-mass spectrometry

• GGR: Global-Genome Repair

• GITR: Glucocorticoid-induced TNF receptor

• **HBsAg:** Hepatitis B surface antigen

• **HBV**: Hepatitis B virus

• HCC: Hepatocellular carcinoma

• HCV: Hepatitis C virus

• **HIV:** Human immunodeficiency virus

• HR: Homologous Recombination

• HVR: Hypervariable regions

• **IFN:** Interferon

• **IFNAR:** IFN-α receptor 1

• **IKKε**: IkappaB kinase epsilon

• **IPS-1**: IFN-β promoter stimulator protein 1

• IRF3: IFN regulatory factor 3

• ISDR: Interferon-sensitivity-determining region

• ISG: IFN stimulated gene

• ISGF3: ISG factor 3

• ISREs: IFN-stimulated response elements

 JAK/STAT: Janus kinase/signal transducer and activator of transcription

• LDLR: Low-density lipoprotein receptor

• MAVS: Mitochondrial antiviral signaling protein

• **MGMT:** Methyl guanine methyl transferase

• MMR: Mismatch repair

• NAFLD: Nonalcoholic fatty liver disease

• **NER:** Nucleotide excision repair

• NF-kb: nuclear factor kappa-light-chain-enhancer of activated B cells

• NHEJ: Non-Homologous End-Joining

NK: natural killer

• **NS**: Nonstructural region

• PCR: Polymerase Chain Reaction

• pDC: plasmacytoid DC

• PI: Propidium iodide

• **PKR:** Protein kinase R

• PP2A: Protein phosphatase 2A

• **Rb:** Retinoblastoma tumor suppressor protein

• RIA: Radio immunoassay

RIBA: Recombinant immunoblot assay

RIG-I: Retinoic acid—inducible gene I

• RNA: RiboNucleic Acid

• SCGE: Single-cell gel electrophoresis-SCGE

• **SOCS**: Suppressor of cytokine signaling

• SSB: Single-Strand Break

• TBK1: TANK-binding kinase 1

• TCR: Transcription-Coupled Repair

• Th1:T helper 1

• Th2:T helper 2

• TLR: Toll-like receptor

• **TLS**: Translesion synthesis

• TNF: Tumor necrosis factor

• Treg: T regulatory cells

• TRIF: TLR3 recruits the adapter molecule Toll–IL-1 receptor domain–containing adaptor inducing IFN-β

TRIF: Toll–IL-1 receptor domain–containing adaptor inducing IFN-β

TUNEL: Terminal deoxyribonucleotidyltransferase mediated deoxyuridine triphosphate nick end labeling assay

• TYK2: Tyrosine kinase

UTR: Untranslated regions

VISA: Virus-induced signaling adapter

LIST OF TABLES

Table (1): Interpretation of HCV Assays14
Table (2): Population-based Cancer Registry Data for Middle Eastern
Countries25
Table (3): Child-Pugh score for assessing hepatic insufficiency64
Table (4): Age distribution for patients and controls
Table (5): Sex distribution for patients and controls78
Table (6): Liver enzymes of control group 79
Table (7): Child score, splenomegaly, ascitis, encephalopathy for cirrhotic
and HCC patients80
Table (8): Laboratory data of HCV patients collectively
Table (9): Laboratory data of seropositive non cirrhotic HCV patients,
cirrhotic and HCC patients82
Table (10): MELD scores for cirrhotic and HCC patients
Table (11): Comparison of the laboratory data between the groups of studied
patients using ANOVA84
Table (12): Comet scores in HCV patients and controls
Table (13): Comparison between controls and HCV patients collectively
regarding the comet scores86
Table (14): Comparison between the 4 groups of studied subjects
regarding the comet scores using ANOVA87
Table (15): Comparison between controls and non cirrhotic sero-positive
HCVcases regarding the Comet scores88
Table (16): Comparison between non cirrhotic sero-positive HCV and
cirrhotic cases regarding the Comet score88

Table (17):	Comparison between cirrhosis and HCC cases regarding the	
	comet scores	89
Table (18):	Comparison between controls and cirrhotic cases regarding	
	the Comet scores	.89
Table (19):	Comparison between controls and HCC cases regarding the	
	Comet scores	.90
Table (20):	Comparison between controls and complicated HCV cases	
	(cirrhotic + HCC) regarding the Comet scores	.90
Table (21):	Correlation between the comet score and the different clinical	
	and laboratory data	91
Table (22):	Multivariate regression analysis for effectors on comet scores	.94
Table (23):	Comparison between HCC patients and HCV with or without	
	cirrhosis regarding DNA damage (mean±2SD of the comet	
	score of controls)	95
Table (24):	Suggested cut off values of the comet score to differentiate	
	HCC from HCV cases with their sensitivity and specificity	96

LIST OF FIGURES

Figure (1): Hepatitis C virus particle structure2
Figure (2): The HCV genome and expressed polyprotein4
Figure (3): The HCV replication cycle7
Figure (4): The natural history of HCV Infection11
Figure (5): HCV attenuates innate immune responses
Figure (6): Regional variation in the estimated incidence rates of liver
cancer24
Figure (7): Proposed procedure for the diagnostic evaluation of a liver
mass in a patient with cirrhosis30
Figure (8): Biological effects of reactive oxygen species (ROS)/reactive
nitrogen species (RNS) in hepatitis C35
Figure (9): Photoreactivation reverses DNA damage44
Figure (10): The repair of double-strand breaks in DNA47
Figure (11): Schematic representation of DNA damage and commonly used
detection strategies49
Figure (12): Schematic representation of the comet assay54
Figure (13): Images of comets (from lymphocytes)58
Figure (14): Correlation between computer image analysis (percentage DNA
in tail) and visual scoring59
Figure (15): Images of lymphocytes showing different classes of DNA
damage using visual scoring70
Figure (16): Image of lymphocytes (comets ranging from 0-2) taken from a
healthy subject71

Figure (17):	Image of lymphocytes (comets ranging from 1-2) taken from
	HCV positive patient without cirrhosis71
Figure (18):	Image of lymphocytes (comets ranging from 2-4) taken from a
(cirrhotic patient72
Figure (19):	Image of lymphocytes (comets ranging from 3-4) taken from a
	patient with HCC72
Figure (20):	Comparison between controls and all patients regarding the
	comet score86
Figure (21):	Mean and standard deviation of the comet score in patients and
	controls87
Figure (22):	Correlation between Comet score and AST level among study
	cases92
Figure (23):	Correlation between Comet score and total bilirubin level among
	study cases92
Figure (24):	Correlation between Comet score and INR among study
	cases93
Figure (25):	Correlation between Comet score and platelet count among
	study cases93
Figure (26):	ROC curve to determine the best cut off of Comet score in
	differentiating HCC from HCV cases96

Abstract

Background and aim of work: A significant proportion of cancer is attributable to DNA damage caused by chronic infection and inflammation. Because hepatitis C virus (HCV) cause chronic infection and inflammatory disease, the aim of the present study was to investigate DNA damage in patients with HCV infection compared with controls and whether there is an association between the level of peripheral DNA damage and hepatocellular carcinoma (HCC). We also aimed to correlate the findings of DNA damage with the clinical and laboratory parameters and to investigate if the comet score is a possible marker for HCC detection.

Methods: Sixty nine patients with HCV (14 patients without cirrhosis, 28 patients with cirrhosis, 27 patients with HCC) and 29 healthy subjects were included in the study. The DNA damage in lymphocytes was determined using the alkaline comet assay.

Results: Comet scores were significantly higher in HCC and cirrhotic patients compared to healthy controls and HCV patients without cirrhosis. Patients who presented with DNA damage had 4.7 fold risk of having HCC more than those with undamaged DNA. At a cutoff of 215, comet scores had 89% sensitivity for detection of HCC.

Conclusions: Ongoing DNA damage in peripheral blood lymphocytes was detected in complicated HCV patients. Thus such a test could be used to detect which patient is at higher risk to develop HCC.

Key words: Comet assay, Hepatitis C virus, Hepatocellular carcinoma.

INTRODUCTION AND AIM OF WORK

Approximately 1.8 million cases of cancer are estimated to be attributable to infectious agents. Viruses such as the hepatitis B and C viruses (HBV and HCV, respectively) are among the most common agents causing cancer (Ohshima et al., 2003). The mechanisms of carcinogenesis associated with infection and inflammation have not been fully elucidated. Three main mechanisms have been proposed to account for infection-associated carcinogenesis: a direct action of the infectious agent on host cells or tissues; immunosuppression; and the production of reactive oxygen and nitrogen species (ROS and RNS, respectively). Prolonged activation of inflammatory cells generate ROS and RNS and these cause tissue and DNA damage that may contribute to the development of cancer (Ohshima et al., 2003).

Chronic liver injury leading to necrosis, inflammation and liver regeneration may progress to cirrhosis and hepatocellular carcinoma (HCC). Hepatitis C virus-related liver damage is characterized by an increase in free radical formation, manifested by increased hepatic and serum levels of products of lipid peroxidation, and accumulation of oxidative DNA damage in the liver (Farinati et al., 1999).

Hepatitis C virus increases the risk of hepatocellular carcinoma (HCC), thus suggesting the possible existence of a genotoxic mechanism. Evidence supporting this hypothesis, however, is still limited and to some extent controversial. Considering that the HCV virus is known to infect peripheral lymphocytes, a direct genotoxic effect of HCV may suggest that the same genotoxic effect may operate in the liver contribute and to hepatocarcinogenesis.

The comet assay (single-cell gel electrophoresis) is a well-established genotoxicity test. Because of its demonstrated ability to detect various types of DNA damage with high sensitivity in eukaryotic cells exposed to genotoxic agents, this technique is being used with greater frequency in humans (Kassie et al., 2000).

Aim of work

The aim of the study is to investigate peripheral DNA damage by the alkaline comet assay in patients with HCV infection (uncomplicated, complicated with liver cirrhosis and HCC on top of cirrhosis) compared to healthy subjects. We also aim to correlate the findings of DNA damage with the clinical and laboratory parameters and to investigate if the comet score is a possible marker for HCC detection.

CHAPTER 1 HEPATITIS C VIRUS INFECTION

Hepatitis C virus (HCV) infects an estimated 170 million persons worldwide and thus represents a viral pandemic, one that is five times as widespread as infection with the human immunodeficiency virus type 1 (HIV-1) (Lauer and Walker,2001).

Structure of HCV virions

HCV circulates in various forms in the serum of an infected host, including (i) virions bound to very—low density lipoproteins and low-density lipoproteins, which appear to represent the infectious fraction; (ii) virions bound to immunoglobulins; and (iii) free virions (Bradley et al.,1991; Thomssen et al.,1993). HCV particles are believed to have a diameter of 55 to 65 nm (Kaito et al.,1994; Shimizu et al.,1996). By analogy with the known 3D structures of closely related flaviviruses and alphaviruses, HCV is thought to adopt a classical icosahedral scaffold in which its two envelope glycoproteins, E1 and E2, are anchored to the host cell-derived double-layer lipid envelope. Underneath the membrane is the nucleocapsid that likely is composed of multiple copies of the core protein, forming an internal icosahedral viral coat that encapsidates the genomic RNA, (fig. 1), (Penin et al.,2004).